Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,800 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 October 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 4MB, 241 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 124 results:
Author Title Type [ Year(Desc)]
Filters: Author is van Staa, T. P.  [Clear All Filters]
1998
T. P. van Staa, Leufkens, H., Abenhaim, L., and Cooper, C., “Postmarketing surveillance of the safety of cyclic etidronate”, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
T. P. van Staa, Abenhaim, L., and Cooper, C., “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
2000
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Begaud, B., Zhang, B., and Cooper, C., “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
2001
T. P. van Staa, Dennison, E. M., Leufkens, H. G., and Cooper, C., “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
T. P. van Staa, Wegman, S., de Vries, F., Leufkens, B., and Cooper, C., “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
2002
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
T. P. van Staa, Selby, P., Leufkens, H. G., Lyles, K., Sprafka, J. M., and Cooper, C., “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
2003
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
T. P. van Staa, Boulton, F., Cooper, C., Hagenbeek, A., Inskip, H., and Leufkens, H. G., “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
P. C. Souverein, van Staa, T. P., Egberts, A. C., De la Rosette, J. J., Cooper, C., and Leufkens, H. G., “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
T. P. van Staa, Cooper, C., Leufkens, H. G., Lammers, J. W., and Suissa, S., “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
2004
T. P. van Staa, Travis, S., Leufkens, H. G., and Logan, R. F., “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
C. Cooper, Dennison, E. M., Leufkens, H. G., Bishop, N., and van Staa, T. P., “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
P. C. Souverein, Berard, A., van Staa, T. P., Cooper, C., Egberts, A. C., Leufkens, H. G., and Walker, B. R., “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
2005
T. P. van Staa, Card, T., Logan, R. F., and Leufkens, H. G., “5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
C. J. Edwards, Arden, N. K., Fisher, D., Saperia, J. C., Reading, I., van Staa, T. P., and Cooper, C., “The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database”, Rheumatology (Oxford), vol. 44, pp. 1394-8, 2005.
P. C. Souverein, Webb, D. J., Petri, H., Weil, J., van Staa, T. P., and Egberts, T., “Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database”, Epilepsia, vol. 46, pp. 304-10, 2005.
G. W. Hugenholtz, Heerdink, E. R., van Staa, T. P., Nolen, W. A., and Egberts, A. C., “Risk of hip/femur fractures in patients using antipsychotics”, Bone, vol. 37, pp. 864-70, 2005.
F. de Vries, van Staa, T. P., Bracke, M. S., Cooper, C., Leufkens, H. G., and Lammers, J. W., “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
T. P. van Staa, Geusens, P., Pols, H. A., de Laet, C., Leufkens, H. G., and Cooper, C., “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
2006
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
F. de Vries, de Vries, C., Cooper, C., Leufkens, B., and van Staa, T. P., “Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database”, Int J Epidemiol, vol. 35, pp. 1301-8, 2006.
K. B. Handoko, Souverein, P. C., van Staa, T. P., Meyboom, R. H., Leufkens, H. G., Egberts, T. C., and van den Bemt, P. M., “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
P. C. Souverein, Webb, D. J., Weil, J. G., van Staa, T. P., and Egberts, A. C., “Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy”, Neurology, vol. 66, pp. 1318-24, 2006.
2007
F. de Vries, Bracke, M., Leufkens, H. G., Lammers, J. W., Cooper, C., and van Staa, T. P., “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
C. J. Edwards, Cooper, C., Fisher, D., Field, M., van Staa, T. P., and Arden, N. K., “The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 57, pp. 1151-7, 2007.
T. P. van Staa, Geusens, P., Zhang, B., Leufkens, H. G., Boonen, A., and Cooper, C., “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
I. Wilting, de Vries, F., Thio, B. M., Cooper, C., Heerdink, E. R., Leufkens, H. G., Nolen, W. A., Egberts, A. C., and van Staa, T. P., “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
F. de Vries, Souverein, P. C., Cooper, C., Leufkens, H. G., and van Staa, T. P., “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
2008
E. Setakis, Leufkens, H. G., and van Staa, T. P., “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
A. M. Gallagher, Rietbrock, S., Olson, M., and van Staa, T. P., “Fracture outcomes related to persistence and compliance with oral bisphosphonates”, J Bone Miner Res, vol. 23, pp. 1569-75, 2008.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
A. M. Gallagher, Rietbrock, S., Plumb, J., and van Staa, T. P., “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?”, J Thromb Haemost, vol. 6, pp. 1500-6, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
2009
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
F. de Vries, Cooper, A. L., Cockle, S. M., van Staa, T. P., and Cooper, C., “Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates”, Osteoporos Int, vol. 20, pp. 1989-98, 2009.
S. Rietbrock, Plumb, J. M., Gallagher, A. M., and van Staa, T. P., “How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database”, Thromb Haemost, vol. 101, pp. 527-34, 2009.
B. Zhang, de Vries, F., Setakis, E., and van Staa, T. P., “The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database”, J Hypertens, vol. 27, pp. 1485-92, 2009.
S. Rietbrock, Olson, M., and van Staa, T. P., “The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates”, Qjm, vol. 102, pp. 35-42, 2009.
T. P. van Staa and Sprafka, J. M., “Study of adverse outcomes in women using testosterone therapy”, Maturitas, vol. 62, pp. 76-80, 2009.
[Page last reviewed 5 October 2021]